Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy
Authors:
- 10 December 2020
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (4) , 905-912
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 31 references indexed in Scilit:
- Dosimetry for Radiopharmaceutical TherapySeminars in Nuclear Medicine, 2014
- MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry ApplicationsJournal of Nuclear Medicine, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide TherapyJournal of Nuclear Medicine, 2012
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide TherapyJournal of Nuclear Medicine, 2010
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- Radionuclide Therapy with Iodine-125 and Other Auger–Electron-Emitting Radionuclides: Experimental Models and Clinical ApplicationsCancer Biotherapy and Radiopharmaceuticals, 2003
- Implementation of a Monte Carlo dosimetry method for patient‐specific internal emitter therapyMedical Physics, 1997
- Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.Proceedings of the National Academy of Sciences, 1986